Synercid
 |
|
Quinupristin (top) and dalfopristin (bottom)
|
|
| Combination of | |
|---|---|
| Quinupristin | Streptogramin antibiotic |
| Dalfopristin | Streptogramin antibiotic |
| Clinical data | |
| Pregnancy category |
|
| Routes of administration |
IV |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
  (what is this?)
|
|
Quinupristin/dalfopristin (pronunciation: kwi NYOO pris tin / dal FOE pris tin) (trade name Synercid) is a combination of two antibiotics used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium.
Quinupristin and dalfopristin are both streptogramin antibiotics, derived from pristinamycin. Quinupristin is derived from pristinamycin IA; dalfopristin from pristinamycin IIA. They are combined in a weight-to-weight ratio of 30% quinupristin to 70% dalfopristin.
Intravenous, usually 7.5 mg/kg every 8–12 hours
Quinupristin and dalfopristin are protein synthesis inhibitors in a synergistic manner. While each of the two is only a bacteriostatic agent, the combination shows bactericidal activity.
Clearance by the liver, half-life 1–3 hours (with persistence of effects for 9–10 hours).
The drug inhibits P450 and enhances the effects of terfenadine, astemizole, indinavir, midazolam, calcium channel blockers, warfarin, cisapride and ciclosporin.
...
Wikipedia